Experts in the industry have shared their experiences during Covid-19 pandemic while drawing attention towards the significance of diverse and resilient supply chain and the challenges posed by import-dependence of APIs during the lockdown.
The Government of India had announced the production linked incentive (PLI) scheme for APIs, KSMs/Dls and bulk drug parks in March 2020 to attain self-reliance and reduce import dependence in critical KSMs/APIs.
This article was originally published on Pharmabiz
